LAUSR

cebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390: 276–8. 3. Vaccaro M, Cannav o SP, Imbesi S et al. Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. Int. J. Dermatol. 2015; 54: 672–4. 4. John JM, Sinclair RD. Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stone [published online ahead of print, 2019 Nov 14]. Australas. J. Dermatol. 2019. 5. Kerkemeyer KLS, Pinczewski J, Sinclair R. Successful treatment of recalcitrant lichen planus pemphigoides with tildrakizumab [published online ahead of print, 2020 Mar 6]. Australas. J. Dermatol. 2020. 6. M ery-Bossard L, Bagny K, Chaby G et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J. Eur. Acad. Dermatol. Venereol. 2017; 31: 181–6.